Vaccines pp 77-84 | Cite as

Effects of Added Cytokines on Immune Responses and Memory

Part of the NATO ASI Series book series (NSSA, volume 215)


Immunological adjuvants can be defined as substances which are not specific to a particular antigen, but which can enhance the specific immune response to antigens. In recent years a new group of such molecules has been defined and partially characterised. These are non-antigen specific molecules which affect specific immune responses in various ways — the cytokines. The increasing availability of cytokines in purified form, as recombinant proteins, has enabled a much increased understanding of their actions and, among many other things, has revealed their usefulness as adjuvants.


Interferon Gamma Rabies Virus Specific Immune Response Malaria Vaccine Adjuvant Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allison, A.C., 1983, Immunological adjuvants and their mode of action, in: “New Approaches to Vaccine Development”, R. Bell and G. Torrigiani, eds., WHO, Schwabe and Co., AG., Basel.Google Scholar
  2. Anderson, G., Urbana, O., Fedorka-Cray, Newell, A., Nunberg, J. and Doyle, M., 1987, Interleukin 2 and protective immunity in Haemophilus pleuropneumoniae. Preliminary studies, in: “Vaccines ’87”, Cold Spring Harbor Press.Google Scholar
  3. Boraschi, D., 1990, Differential activity of interleukin la and interleukin lb in the stimulation of immune responses in vivo, Eur.J.Immunol., 20:317.PubMedCrossRefGoogle Scholar
  4. Flexner, C., Hugin, A. and Moss, B., 1987, Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression, Nature, 330:259.PubMedCrossRefGoogle Scholar
  5. Frasca, D., Boraschi, D., Baschierl, S., Bossu, P., Tagliabue, A., Adorini, L. and Doria, G., 1989, In vivo restoration of T cell function by human IL-1β or its 16–171 nonapeptide in inwunodepressed mice, J.Immunol., 141:2651.Google Scholar
  6. Ghiara, P., Borashi, D., Nencioni, L., Ghezzi, P. and Tagliabue, A., 1988, Enhancement of in vivo immune response by tumour necrosis factor, J.Immunol., 139:3676.Google Scholar
  7. Good, M.F., Pombo, D., Lunde, M.N., Maloy, W.L., Halenbeck, R., Koths, K., Miller, L.H. and Berzofsky, J.A., 1988, Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides, J.Immunol., 141:972.PubMedGoogle Scholar
  8. Grun, J.L. and Maurer, P.H., 1989, Different T helper subsets elicited in mice utilising two different adjuvant vehicles; the role of endogenous interleukin in proliferative responses, Cell Immunol., 121:134.Google Scholar
  9. Heath, A.W. and Playfair, J.H.L., 1991, Conjugation of interferon gamma to antigen enhances its adjuvant ici ty, Immunology, in press.Google Scholar
  10. Heath, A.W., Devey, M.E., Brown, I.N., Richards, C.E. and Playfair, J.H.L., 1989a, Interferon gamma as an adjuvant in immunocompromised mice, Immunology, 67:520.PubMedGoogle Scholar
  11. Heath, A.W., Haque, N.A., De Souza, J.B. and Playfair, J.H.L., 1989b, Interferon gamma as an effective immunological adjuvant, in: “Vaccines ’89”, Cold Spring Harbor Press.Google Scholar
  12. Heath, A.W., Nyan, O., Richards, C.E. and Playfair, J.H.L., 1991, Effects of interferon gamma and saponin in lymphocyte traffic are inversely related to adjuvanticity and enhanced MHC class II expression, Int.Immunol., 3:285.PubMedCrossRefGoogle Scholar
  13. Kawamura, H., Rosenberg, S. and Berzofsky, J.A., 1985, Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness, J.Exp.Med., 162:381.PubMedCrossRefGoogle Scholar
  14. Kohonen-Corish, M.R.J., King, N.J.C., Woodhams, C.E. and Ramshaw, I.A., 1990, Immunodeficient mice recover from infection with vaccinia virus expressing interferon gamma, Eur.J.Immunol., 20:157.PubMedCrossRefGoogle Scholar
  15. Lichtmann, A.H., Chin, J., Schmidt, J.A. and Abbas, A.K., 1988, Role of interleukin 1 in the activation of T lymphocytes, Proc.Nat.Acad.Sci.USA., 85:9699.CrossRefGoogle Scholar
  16. Meiler, S.C., Dumaim, H., Meyer zum Buschenfelde, K.H. and Kohler, H., 1989, Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination, Lancet, i:15.Google Scholar
  17. Moore, K.W., Viera, P., Florentino, D.F., Trounstine, M.L., Khan, T.A. and Mosman, T.R., 1990, Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1, Science, 248:1230.PubMedCrossRefGoogle Scholar
  18. Mosman, T.R. and Coffman, R.L., 1989, Different patterns of lymphokine secretion lead to different functional properties, Ann.Rev.Immunol., 7:145.CrossRefGoogle Scholar
  19. Nencioni, L., Villa, L., Tagliabue, A., Antoni, G., Presentini, R., Perin, F., Silvestre, A. and Boraschi, D., 1987, In vivo immunostiimilating activity of the 163–171 peptide of human IL-1β, J.Immunol., 139:800.PubMedGoogle Scholar
  20. Nunberg, J., Doyle, M.V., York, S.M. and York, C.J., 1989, Interleukin 2 acts as an adjuvant to enhance the potency of inactivated rabies virus vaccine, Proc.Nat.Acad.Sei.USA., 86:4230.CrossRefGoogle Scholar
  21. Playfair, J.H.L. and De Souza, J.B., 1987, Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice, Clin.Exp.Immunol., 67:5.PubMedGoogle Scholar
  22. Quiroga, J.A. and Carreno, V., 1989, Interferon and hepatitis B vaccine in haemodialysis patients, Lancet, ii:1264.Google Scholar
  23. Ramshaw, I.A., Andrew, M.E., Phillips, S.M.N., Boyle, D.B. and Coupar, B.E.H., 1987, Recovery of immunodeficient mice from a vaccinia virus/IL2 recombinant infection, Nature, 329:545.PubMedCrossRefGoogle Scholar
  24. Redfield, R.R., Wright, D.C., James, W.D., Jones, T.S., Brown, C. and Burke, J.S., 1987, Disseminated vaccinia in a military recruit with human immunodeficiency disease, New Eng.J.Med., 316:673.PubMedCrossRefGoogle Scholar
  25. Reed, S.G., Pihl, D.K., Cordon, P.J. and Grabstein, K.H., 1989a, IL1 as adjuvant. Role of T cells in the augmentation of specific antibody production by recombinant human IL1α, J.Immunol., 142:3129.PubMedGoogle Scholar
  26. Reed, S.G., Pihl, D.K., Grabstein, K.H., 1989b, Immune deficiency in chronic Trypanosoma cruzi infection. Recombinant IL1 restores T helper function for antibody production, J.Immunol., 142:2067.PubMedGoogle Scholar
  27. Scott, P., Pearch, E., Cheever, A.W., Coffman, R.L. and Sher, A., 1989, Role of cytokines and CD4+ T cell subsets in the regulation of parasite immunity and disease, Immun.Rev., 112:161.PubMedCrossRefGoogle Scholar
  28. Snapper, CM. and Paxil, W.E., 1987, Interferon gamma and B cell stimulatory factor-1 reciprocally regulate immunoglobulin isotype production, Science, 236:944.PubMedCrossRefGoogle Scholar
  29. Staruch, M.J. and Wood, D.D., 1983, The adjuvanticity of interleukin 1 in vivo, J.Immunol., 130:2191.PubMedGoogle Scholar
  30. Talmadge, J.E., Phillips, H., Schneider, M., Rowe, T., Pennington, R., Bowersox, O. and Lenz, B., 1988, Immunomodulatory properties of recombinant murine and human tumour necrosis factor, Cancer Res., 48:544.PubMedGoogle Scholar
  31. Weaver, C.T., Hawrylowicz, CM. and Uhanue, E.R., 1988, T helper cell subsets require the expression of distinct costimulatory signals by antigen presenting cells, Proc.Nat.Acad.Sei.USA., 85:8181.CrossRefGoogle Scholar
  32. Weinberg, A. and Merigan, T.C., 1988, Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with Herpes simplex virus subunit vaccines, J.Immunol., 140:294.PubMedGoogle Scholar
  33. Yilma, T., Breeze, R.G., Ristow, S., Gorham, J. and Leib, S.R., 1985, Immune response of cattle and mice to the G glycoprotein of vesicular stomatitis virus, Adv.Exp.Med.Biol., 185:101.PubMedCrossRefGoogle Scholar
  34. Yilma, T., Anderson, K., Brechling, K. and Moss, B., 1987, Expression of an adjuvant gene (interferon-y) in infectious vaccinia virus recombinants, in: “Vaccines ’87”, Cold Spring Harbor Press.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  1. 1.Paravax Inc.Mountain ViewUSA
  2. 2.Department of ImmunologyUCMSMLondonUK

Personalised recommendations